Company: CERO
Filing Date: 2025-11-17
Form Type: PRE 14A
Source: 0001213900-25-111175
Chunk: 16

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-17
Form: PRE 14A
Chunk 16
---
 of the amendment with the Secretary of State, the Board of Directors, in its sole discretion, determines that it is no longer in our best interest and the best interests of our stockholders to proceed. The proposed form of amendment to our Certificate of Incorporation to effect the Reverse Stock Split is attached as Appendix A to this proxy statement. Any amendment to our Certificate of Incorporation to effect the reverse stock split will include the reverse stock split ratio fixed by the Board, within the range approved by our stockholders. Reasons for the Reverse Stock Split On October29, 2025, we received the determination of the Nasdaq Hearings Panel (the “Panel”) to deny our request to continue the listing of our Common Stock on Nasdaq and that the trading in our securities would be suspended at the open of trading on October31, 2025. We submitted a request for review of the Panel’s decision by the Nasdaq Listing and Hearing Review Council. On October31, 2025, our Common Stock commenced trading on the OTC Pink Sheets under the symbol “CERO”. Our primary objective in effectuating the Reverse Stock Split would be to attempt to raise the per -sharetrading price of our Common Stock to meet Nasdaq’s listing requirements, which requires, among other things, that our Common Stock have a per share bid price that is greater than or equal to $1.00 per share (the “Bid Price Requirement”) and thereby potentially regain listing on Nasdaq. On November12, 2025, the closing bid price for our Common Stock on the OTC Pink Sheets was $0.0990 per share. The Board also believes that a higher stock price may help generate investor interest in the Company. If the Reverse Stock Split successfully increases the per share price of our Common Stock, the Board of Directors also believes this increase may increase trading volume in our Common Stock and facilitate future financings by the Company. 7 As a result of our prior reverse stock splits, we are not entitled to a cure period for our failure to comply with the Bid Price Requirement within one year after our most recent reverse stock split. Failure to approve the Reverse Stock Split may have serious, adverse effects on the Company and its stockholders. Our shares are quoted on the OTC Bulletin Board or other small trading markets, which are generally considered to have less volume and be less efficient markets. We believe an investor likely would find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our Common Stock on an over -the-counter